DOUGLAS MARKS

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NEW YORK, NY NPI 1083980189

General Payments — all program years on this page

$29,803.95

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 47
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $13,958.65 across 30 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $11,675.005
Long term medical supply or device loan $1,081.8112
Travel and Lodging $689.103
Food and Beverage $512.7410

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Gilead Sciences, Inc. $6,222.389
Acerta Pharma LLC $5,065.003
Daiichi Sankyo Inc. $1,513.002
NOVARTIS PHARMACEUTICALS CORPORATION $1,144.8615
Tempus AI, Inc $13.411

By program year

Program yearAmountRecords
2018 $193.092
2020 $1,375.001
2021 $11.921
2022 $167.473
2023 $14,097.8210
2024 $13,958.6530

Records — PY2024 (30)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086975894 Novartis Pharmaceuticals Corporation $10.00 02/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086975906 Novartis Pharmaceuticals Corporation $20.80 07/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086975912 Novartis Pharmaceuticals Corporation $83.33 08/23/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975914 Novartis Pharmaceuticals Corporation $83.33 09/27/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975918 Novartis Pharmaceuticals Corporation $99.70 01/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975920 Novartis Pharmaceuticals Corporation $99.70 02/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975922 Novartis Pharmaceuticals Corporation $99.70 03/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975924 Novartis Pharmaceuticals Corporation $99.70 04/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975926 Novartis Pharmaceuticals Corporation $99.70 05/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975928 Novartis Pharmaceuticals Corporation $83.33 06/13/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975930 Novartis Pharmaceuticals Corporation $83.33 07/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975934 Novartis Pharmaceuticals Corporation $83.33 11/14/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975938 Novartis Pharmaceuticals Corporation $83.33 10/17/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086975946 Novartis Pharmaceuticals Corporation $32.25 12/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086975948 Novartis Pharmaceuticals Corporation $83.33 12/10/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1089452468 Daiichi Sankyo Inc. $1,370.00 02/21/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1089452470 Daiichi Sankyo Inc. $143.00 12/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104532846 AstraZeneca Pharmaceuticals LP $2,055.00 10/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104593606 AstraZeneca Pharmaceuticals LP $1,640.00 11/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105577102 AstraZeneca Pharmaceuticals LP $1,370.00 08/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1133599303 Gilead Sciences, Inc. $5,240.00 06/25/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1133794817 Gilead Sciences, Inc. $21.14 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133794819 Gilead Sciences, Inc. $28.86 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133794821 Gilead Sciences, Inc. $49.99 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133794823 Gilead Sciences, Inc. $52.38 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133794825 Gilead Sciences, Inc. $140.91 06/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133865999 Gilead Sciences, Inc. $261.00 06/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1133866001 Gilead Sciences, Inc. $297.53 06/20/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1133866003 Gilead Sciences, Inc. $130.57 06/25/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1150169332 Tempus AI, Inc $13.41 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.